SKYSCRAPER-06...a study that randomized patients t
Post# of 145345
![](/assets/46931549/no_avatar_available_thumb.jpg)
Roche found the survival rate favored the KEYTRUDA regimen at the First Interim Analysis.
The assessment of (PFS) generated a hazard rate of 1.27...Anything above 1. indicates the Control group performed better than the Investigational Treatment. ALL indications suggest KEYTRUDA patients are living LONGER. Roche at closing down 2%.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)